MyFinsight
Home
Blog
About
Maturities of marketable
securities
$57,662K
(-78.37%↓ Y/Y)
Net cash provided by
(used in) investing...
$7,094K
(5.72%↑ Y/Y)
Canceled cashflow
$50,568K
Net change in cash,
cash equivalents,...
-$4,916K
(-106.52%↓ Y/Y)
Canceled cashflow
$7,094K
Proceeds from issuance of
common stock
$4,123K
(-22.47%↓ Y/Y)
Intangible asset
impairment charges
$54,919K
Depreciation and
amortization
$25,747K
(-38.32%↓ Y/Y)
Prepaid expenses and
other assets
-$21,659K
(-344.74%↓ Y/Y)
Accrued product returns
and rebates
$9,124K
(-25.28%↓ Y/Y)
Share-based compensation
expense
$8,640K
(-44.53%↓ Y/Y)
Inventory valuation
write-down
$4,049K
(176.01%↑ Y/Y)
Noncash lease expense
$2,196K
Other noncash
adjustments, net
-$294K
(92.22%↑ Y/Y)
Purchases of marketable
securities
$50,000K
(-80.70%↓ Y/Y)
Purchases of property and
equipment
$568K
(-27.37%↓ Y/Y)
Net cash provided by
(used in) financing...
-$7,200K
(64.82%↑ Y/Y)
Canceled cashflow
$4,123K
Net cash provided by
operating activities
-$4,810K
(-105.40%↓ Y/Y)
Canceled cashflow
$126,628K
Total revenues
$219,058K
(-30.52%↓ Y/Y)
Payment of contingent
consideration
$11,235K
(-49.83%↓ Y/Y)
Employee taxes paid
related to net share...
$88K
(-97.40%↓ Y/Y)
Net earnings (loss)
-$58,371K
(-646.95%↓ Y/Y)
Canceled cashflow
$219,058K
Accounts receivable
$29,474K
(2465.49%↑ Y/Y)
Payment of contingent
consideration
$22,208K
(-0.84%↓ Y/Y)
Deferred income tax
benefit
-$16,949K
(-51.98%↓ Y/Y)
Accounts payable and
other liabilities
-$3,790K
(-48.80%↓ Y/Y)
Amortization of
premium/discount on marketable...
$340K
(-69.26%↓ Y/Y)
Inventories
$306K
(103.18%↑ Y/Y)
Other segment items
$80,660K
(104.32%↑ Y/Y)
Selling expenses
$68,910K
(-20.80%↓ Y/Y)
General and
administrative expenses
$40,846K
(-25.85%↓ Y/Y)
Cost of revenues
$33,669K
(3.31%↑ Y/Y)
Total research and
development expenses
$29,463K
(-39.92%↓ Y/Y)
Marketing expenses
$23,881K
(-42.31%↓ Y/Y)
Total external
development program...
$18,864K
(-33.97%↓ Y/Y)
Internal
employee-related expenses
$10,599K
(-48.23%↓ Y/Y)
SPN817
$6,943K
(-1.05%↓ Y/Y)
Early Stage Program
And Other
$5,102K
(-23.76%↓ Y/Y)
SPN820
$2,968K
(-57.37%↓ Y/Y)
Qelbree
$2,217K
(-66.60%↓ Y/Y)
SPN443
$1,046K
ONAPGO
$515K
(-59.16%↓ Y/Y)
ZURZUVAE
$73K
Back
Back
Cash Flow
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
source: myfinsight.com